Human papillomavirus disease in adolescents: Management and prevention

Adolescent Medicine: State of the Art Reviews

Volumn 23, Issue 1, 2012, Pages 192-206

  Widdice, Lea E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871875432     PISSN: 19344287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Barrasso R, De Brux J, Croissant O, Orth G. High prevalence of papillomavirus-associated penile intraepithelial neoplasia in sexual partners of women with cervical intraepithelial neoplasia. N Engl] Med. 1987;317(15):916-923
2. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423-428
3. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. / Pediatr. 1998; 132(2):277-284
4. Trottier H, Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics. 2009;12(5-6):291-307
5. Kashima HK, Shah F, Lyles A, et al. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope. 1992;102(1):9-13
6. Larson DA, Derkay CS. Epidemiology of recurrent respiratory papillomatosis. APMIS. 2010;118(6-7):450-454
7. ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 109. Cervical Cytology Screening. Obstet Gynecol. 2009; 114:1409-1420
8. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008; 168(2): 123-137
9. Motoyama S, Ladines-Llave CA, Luis Villanueva S, Maruo T. The role of human papilloma virus in the molecular biology of cervical carcinogenesis. Kobe J Med Sci. 2004;50(l-2):9-19
10. Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis. 1999;26(4 Suppl):S2-7
11. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev. 1988;10:122-163
12. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813-819
13. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366(9490):991-998
14. Weaver BA, Feng Q, Holmes KK, et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. / Infect Dis. 2004;189(4):677-685
15. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis. 2006;6(1):21-31
16. Chin-Hong PV, Vittinghoff E, Cranston RD, et aL Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis. 2004;190(12):2070-2076
17. Smith EM, Swarnavel S, Ritchie JM, Wang D, Haugen TH, Turek LP. Prevalence of human papillomavirus in the oral cavity/oropharynx in a large population of children and adolescents. Pediatr Infect Dis J. 2007;26(9):836-840
18. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral Sexual Behaviors Associated with Prevalent Oral Human Papillomavirus Infection. / Infect Dis. 2009;199(9):1263-1269
19. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354(25):2645-2654
20. Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG. 2002;109(l):96-98
21. Winer RL, Feng Q, Hughes JP, O'Reilly S, Kiviat NB, Koutsky LA. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis. 2008;197(2):279-282
22. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3):218-226
23. Castellsague X, Munoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003(31):20-28
24. Rintala MA, Grenman SE, Puranen MH, et al. Transmission of high-risk human papillomavirus (HPV) between parents and infant: a prospective study of HPV in families in Finland. / Clin Microbiol. 2005;43( 1 ):376-381
25. Mount SL, Papillo JL. A study of 10,296 pediatric and adolescent Papanicolaou smear diagnoses in northern New England. Pediatrics. 1999;103(3):539-545
26. Moscicki AB, Shiboski S, Hills NK, et aL Regression of low-grade squamous intra-epithelial lesions in young women. Lancet. 2004;364(9446):1678-1683
27. Syrjanen K, Kataja V, Yliskoski M, Chang F, Syrjanen S, Saarikoski S. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol. 1992;79(5 ( Pt l)):675-682
28. Schlecht NF, Platt RW, Duarte-Franco E, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst. 2003;95( 17): 1336- 1343
29. Moscicki AB, Ma Y, Wibbelsman C, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010;116(6):1373-1380.
30. Wheeler CM. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer. Obstet Gynecol Clin North Am. 2008;35(4):519-536; vii
31. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. / Natl Cancer Inst. 2002;94(18):1406-1414
32. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24 Suppl 3:S42-51
33. Castle PE, Giuliano AR. Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients-assessing their roles as human papillomavirus cofactors. ] Natl Cancer Inst Monogr. 2003(31):29-34
34. Hildesheim A, Herrero R, Castle PE, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. BrJ Cancer. 2001;84(9):1219-1226
35. Hogewoning CJ, Bleeker MC, van den Brule AJ, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical triaL Int] Cancer. 2003;107(5):811-816
36. Saraiya M, Ahmed F, Krishnan S, Richards TB, Unger ER, Lawson HW. Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet Gynecol. 2007;109(2 Pt l):360-370
37. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527
38. Appleby P, Beral V, Berrington de Gonzalez A, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118(6):1481-1495
39. Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003;361(9364):1159-1167
40. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. Vol 562007:1-24
41. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24S3:S1-S10
42. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. 2007; http://seer.cancer.gov/csr/1975- 2004/
43. Giuliano AR, Anic G, Nyitray AG. Epidemiology and pathology of HPV disease in males. Gynecol Oncol. 2010;117(2 Suppl):S15-19
44. Ryerson A, Peters E, Coughlin S, et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer. 2008; 113
45. Kjaer SK, Munk C, Winther JF, Jorgensen HO, Meijer CJ, van den Brule AJ. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev. 2005;14(6):1528-1533
46. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1-110
47. Centers for Disease Control and Prevention. VFC: The ACIP-VFC Vaccine Resolutions, http:// www.cdc.gov/vaccines/programs/vfc/acip-vfc-resolutions.htm. Accessed November 11,2011
48. Block SL, Nolan T, Sattler C, et al. Comparison of the Immunogenicity and Reactogenicity of a Prophylactic Quadrivalent Human Papillomavirus (Types 6,11,16, and 18) LI Virus-Like Particle Vaccine in Male and Female Adolescents and Young Adult Women. Pediatrics. 2006; 118(5):2135-2145
49. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943
50. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent LI virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369(9580):2161-2170
51. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 LI virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis }. 2007;26(3):201-209
52. Food and Drug Administration. Product approval-prescribing information [package insert]. Cer-varix [human papillomavirus bivalent (types 16 and 18) vaccine, recombinant], 2009; http://www. fda.gov/biologicsbloodvaccines/ vaccines/approvedproducts/ucml86957.htm Accessed May 25, 2010
53. Gardasil [Package Insert], Whitehouse Station, NJ: Merck 8: Co., Inc.; 2006
54. Food and Drug Administration. Product approval-prescribing information [package insert]. Human Papillomavirus Quadrivalent (Types 6,11,16,18) Vaccine, Recombinant. 2011; http://www.fda.gov/ BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UCM094042. Accessed October 25,2011
55. Villa LL, Ault KA, Giuliano A, et al. Immunologic responses following administration of a vacine targeting human papillomavirus Types 6,11,16, and 18. Vaccine. 2006;24:5571-5583
56. Slade B, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302(7):750
57. Centers for Disease Control and Prevention. Youth risk behavior surveillance-United States, 2009. MMWR Surveill Summ. 2010;59(No. SS-5):1-142
58. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367(9509):489-498
59. American Cancer Society. Early detection of cervical cancer. CA Cancer J Clin. 2002 2002;52:375-376
60. U.S. Preventive Services Task Force. Screening for Cervical Cancer, Topic Page. http://www.ahcpr. gov/clinic/uspstf/uspscerv.htm. Accessed October 26,2011